Featured
-
MUMBAI, India, Oct. 27, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2026. Consolidated Financial Highlights…
Highlighted
-
MUMBAI, India, Oct. 27, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced…
-
Former Global CTO of Banco Santander, former Group CIO of Currys, former CEO of IBPAP, and former Microsoft CVP and CTO of AI join the…
-
MUMBAI, India, Oct. 27, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced…
-
Consolidated revenues for the first nine months of 2026 reached AED 57.6 billion, an increase of 10.0 per cent YoY Consolidated net profit for the first…
-
Memorandum of Understanding (MoU) announced at Singapore International Energy Week 2026 Combines Seatrium’s offshore engineering expertise with Karpowership’s proven leadership in floating power to pursue…
-
The strategic evolution brings together more than 4,000 hotels across 100 countries and introduces WorldHotels Rewards™, a unified loyalty program launching Jan. 5, 2027 PHOENIX,…